AroCell: Q4’21 review - Redeye

Redeye returns with a more detailed take on the Q4 report with some estimate changes, primarily for the two coming years. We reiterate our fair value range, suggesting a hefty upside from today’s share price levels, but emphasize the market volatility and an overhang from guarantors’ commitments from the rights issue.

Länk till analysen i sin helhet: https://www.redeye.se/research/834979/arocell-q421-review?utm_source=finwire&utm_medium=RSS